NBOMes: Difference between revisions
No edit summary |
No edit summary |
||
| Line 133: | Line 133: | ||
25i-NBOMe, 25b-NBOMe, and 25c-NBOMe were emergency scheduled by the DEA on Novemeber 15, 2013<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref> | 25i-NBOMe, 25b-NBOMe, and 25c-NBOMe were emergency scheduled by the DEA on Novemeber 15, 2013<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref> | ||
= Images = | |||
<gallery mode="packed-hover"> | |||
Image:25b.jpg|''25b'' | |||
Image:25c.jpg|''25c'' | |||
Image:25i.jpg|''25i'' | |||
</gallery> | |||
= Links = | = Links = | ||
Revision as of 13:16, 14 October 2014
These chemicals have nearly no history of human use prior to 2010 when they first became available online, and very little is known about this group of compounds. They should only be used with extreme caution. It's recommended to not take more than 1.5 mg of any substance of the NBOMe family, as there have been multiple deaths from people just taking 2-3 blotters.
25I-NBOMe Dosage
Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect). NBOMe chemicals are not active orally, and will not work if swallowed. It is recommended to avoid sublingual administration because of the reported bad taste. Buccal administration is common, placing the tab between the upper or lower gum and lip.
| Light | 200-500 μg |
| Common | 500-1500 μg |
| Strong | 1500+ μg |
| Light | 100-400 μg |
| Common | 400-700 μg |
| Strong | 700+ μg+ |
25C-NBOMe Dosage
Effects have been reported to vary very strongly by person (for example: person A gets a 4-hour body high with barely any visual aspects, while person B gets a >12 hour DOB-like trip with an intense visual aspect).
| Light | 100-300 μg |
| Common | 300-800 μg |
| Strong | 800+ μg |
| Light | 100-300 μg |
| Common | 300-500 μg |
| Strong | 500+ μg |
Duration
| Onset | 15-45 minutes |
| Total | 4-11 hours |
| Onset | 0-10 minutes |
| Total | 3-8 hours |
Effects
Positive
- Strong open and closed eye visuals, including trails, color shifts, brightening, etc.
- Mood lift
- Euphoria
- Mental and physical stimulation
- Increase in associative & creative thinking
- Increased awareness & appreciation of music
- Life-changing spiritual experiences
- Erotic, sexual thoughts and sensations
- Feelings of love and empathy
Neutral
- General change in consciousness
- Pupil dilation
- Difficulty focusing
- Unusual body sensations (facial flushing, chills, goosebumps, body energy)
- Change in perception of time, time dilation
- Slight increase in heart rate
- Yawning, especially when coming up
Negative
Likelihood of negative side effects increases with higher doses.
- Confusion
- Looping
- Scrambled communication
- Nausea
- Insomnia
- Looping, recursive, out of control thinking
- Paranoia, fear, and panic
- Unwanted and overwhelming feelings
- Unwanted life-changing spiritual experiences
After effects
- Afterglow
- An afterglow may be present until a day after use, sometimes more depending on the individual.
- Long term effects
- A relatively high rate of HPPD has been reported (all anecdotal data!) after the use of the NBOMe chemicals.
Harm Reduction
NBOMes are considered less safe than many psychedelics, as they generally have a much lower threshold for overdose and have a much heavier physical effect on the body. Even so, most reports of death by an NBOMe chemical involve mislabeling of the drug (for example: someone insufflates 20mg of 25i-NBOMe because he/she thought it was 2C-I). This chemical is extremely potent and has a relatively low LD50 (LD50 is the dosage at which 50% of the tested population does not survive). Therefore, a mislabeling or misweighing can result in death.
Furthermore, due to the physical strain the drug causes one should not use it if there are any pre-existing heart conditions.
See Psychedelic Harm Reduction for general information.
Legal status
Europe
The NBOMe series of psychoactives became controlled in the Russian Federation] starting October, 2011.[1]
The UK Home Office announced that 25I-NBOMe would be made a class A drug on 10th June 2014 alongside every other N-benzyl phenethylamines.[2]
America
25i-NBOMe, 25b-NBOMe, and 25c-NBOMe were emergency scheduled by the DEA on Novemeber 15, 2013[3]
Images
-
25b
-
25c
-
25i
